TGTX Stock Alert: What to Know as Takeover Rumors Swirl Around TG Therapeutics

TG Therapeutics (TGTX) shares experienced a significant surge on August 21 as rumors of a potential takeover started circulating. The company's stock price rose after an unverified alert from Betaville suggested a U.S. biopharma company with a market capitalization between $20 billion and $40 billion might be interested in acquiring TG Therapeutics. Since then, TG Therapeutics' stock has increased by approximately 85% compared to the beginning of the year.

Investors should be aware that the Betaville report did not specify the potential acquirer, and there has been no confirmation from TG Therapeutics regarding ongoing takeover discussions. While a takeover rumor can boost a biotech stock as investors anticipate an acquisition premium, these gains can disappear quickly if the speculation is refuted or an acquisition does not materialize.

Nevertheless, TG Therapeutics' fundamentals provide a rationale for strategic interest. In the second quarter, the company's U.S. revenue from BRIUMVI reached $227.7 million, a 64% increase year-over-year. Furthermore, TGTX raised its 2026 revenue target to around $950 million. The company remains profitable and continues to invest aggressively in commercial and pipeline opportunities, offering a plausible underlying business story amidst the speculation.

However, investors should differentiate between the firm's operating performance and an unverified buyout thesis. Unless a potential suitor emerges or TGTX confirms discussions, the takeover-driven premium from Friday might prove volatile. For investors who appreciate the underlying business, waiting for the takeover excitement to subside and searching for a more advantageous entry could present a better risk-reward than reacting to the momentum on August 21.

Despite volatility risks, Wall Street remains optimistic about TGTX shares for the remainder of 2026, with the consensus rating at "Moderate Buy" and a mean price target around $64, suggesting an additional 17% upside from the current price.